References:
  1. Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
  2. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-36.
  3. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new deinition. J Atheroscler Thromb 2005; 12: 295- 300.
  4. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K: Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002, 11:385–391.
  5. Hammarsten and Peeker R. Nat Rev Urol. Urological aspects of the metabolic syndrome. 2011; 8 : 483-94
  6. Gorbachinsky et al. Rev Urol. Metabolic syndrome and urological diseases. 2010; 12 : 157-80
  7. Chu et al. Postgrad Med. The impact of obesity on benign and malignant urologic conditions 2013; 125 : 53-69
  8. Motzer Rj, Agarwal N, Beard C, et al. Kidney cancer clinical practice guidelines in oncology. J Natl Compr CAnc Netw 9:960-977,2011
  9. Campbell SC, Lane BR. Malignant renal tumors. In: Kavoussu LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology. 10th ed. Philedelphia: Saunders 2012; 1413.
  10. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006;169:1505-22.
  11. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and survival in patients with renal cell carcinoma: A clinical-based cohort and meta-analysis. Int J Cancer 2013 Feb 1;132(3):625-34
  12. Lipworth L, Tarone RE, Lund L, McLaughlin JK. Epidemiologic characteristics and risk factors for renal cell cancer. Clin Epidemiol 2009;1:33-43.
  13. Navai N, Wood CG. Environmental and modifiable risk factors in renal cell carcinoma. Urol Oncol 2012;30:220-4.
  14. Robson CJ. Staging of renal cell carcinoma. Prog Clin Biol Res. 1982;100:439-45.
  15. Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. Eighth edition. ed. xvii, 1,024 pages p
  16. Atan A. Metabesity and urological cancers. Turk J Urol. 2017 Dec;43(4):410-413. doi: 10.5152/tud.2017.66502. Epub 2017 Dec 1. Review.
  17. Zucchetto A, Dal Maso L, Tavani A ve ark. History of treated hypertension and diabetes mellitus and risk of renal cell cancer. Ann Oncol 2007; 18: 596-600.
  18. Hajdu SI, Thomas AG (1967) Renal cell carcinoma at autopsy. J Urol 97: 978±982
  19. Whisenand JM, Kostas D, Sommers SC (1962) Some Host Factors in the Development of Renal Cell Carcinoma. West J Surg Gynecol 70: 284±285
  20. Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999, 42:107–112.
  21. Joh HK, Willett WC, Cho E: Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 2011, 34:1552–1556.
  22. Lee H, Kwak C, Kim HH, et al. Diabetes mellitus as an independent predictor of survival of patients surgically treated for renal cell carcinoma: A propensity score matching study. J Urol. 194:1554–1560. 2015.
  23. Fukushima H, Masuda H, Yokoyama M, et al. Diabetes mellitus with obesity is a predictor of recurrence in patients with non-metastatic renal cell carcinoma. Jpn J Clin Oncol. 43:740–746. 2013.
  24. Otunctemur A, Ozbek E, Sahin S, et al. Diabetes mellitus as a risk factor for high grade renal cell carcinoma. Asian Pac J Cancer Prev. 2014;15(9):3993-6
  25. Li M, Liu J, Hu WL, et al. Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms. Nan Fang Yi Ke Da Xue Xue Bao 2011, 31:1504–1508.
  26. Liu J, Li M, Song B, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013, 31:264–270.
  27. Habib SL, Prihoda TJ, Luna M, Werner SA (2012). Diabetes and risk of renal cell carcinoma. J Cancer , 3, 42-8.
  28. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B: Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000, 343:1305–1311.
  29. Colt JS, Schwartz K, Graubard BI,et al. : Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011, 22:797–804.
  30. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 Dec;176(6 Pt 1):2353-8.
  31. Grossman E, Messerli FH, Goldbourt U: Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999, 83:1090–1093
  32. Wulaningsih W, Garmo H, Holmberg L,et al. Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. J Cancer Epidemiol 2012, 2012:792034.
  33. Inoue M, Noda M, Kurahashi N, et al.Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009, 18:240–247.
  34. Horiguchi A, Ito K, Sumitomo M, et al. Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2008, 38:106–111.
  35. Drabkin HA, Gemmill RM (2012) Cholesterol and the development of clear-cell renal carcinoma. Curr Opin Pharmacol 12(6):742–750
  36. Eichholzer M, Stahelin HB, Gutzwiller F, et al. (2000). Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr , 71, 569-74.
  37. Bowers K, Albanes D, Limburg P, et al (2006). A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol , 164, 652-64.
  38. Meilahn EN, Ferrell RE. ‘Naturally occurring’ low blood cholesterol and excess mortality. Coron Artery Dis 1993;4:843–53.
  39. Bjørge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol. 2004 Dec 15;160(12):1168-76.
  40. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006 Feb 1;118(3):728-38.
  41. Haggstrom C, Rapp K, Stocks T et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 2013;8:e57475.
  42. Leiba A, Kark JD, Afek Adolescent obesity and paternal country of origin predict renal cell carcinoma: a cohort study of 1.1 million 16 to 19-year-old males. J Urol 2013, 189:25–29.
  43. Parker AS, Lohse CM, Cheville JC, et al (2006). Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urol , 68, 741.